TARRYTOWN, N.Y., June 05, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 6, 2023 at 1:00 p.m. ET. The following week, the Company will participate in a fireside chat at the Oppenheimer Consumer Growth & E-Commerce Conference virtually on Monday, June 12, 2023 at 9:45 a.m. ET.
All interested parties may access a live webcast of these events at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
https://ir.prestigebrands.com/events-presentations/events
For those unable to participate during the live webcasts, a replay option will be available on the Company’s website following the event.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse and iconic portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$67.90 |
Daily Change: | 0.64 0.95 |
Daily Volume: | 119,454 |
Market Cap: | US$3.340B |
June 09, 2025 February 06, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load